Can Skinny People Get Fatty Liver Disease?

Can skinny people get fatty liver disease? Yes, and it is more common than many people realise. Lean non-alcoholic fatty liver disease, now also termed lean metabolic dysfunction-associated steatotic liver disease (lean MASLD), affects individuals with a normal or low body mass index. Excess fat can accumulate in liver cells due to genetic factors, insulin resistance, and lifestyle influences that operate entirely independently of body weight. Because fatty liver disease is so strongly associated with obesity in public awareness, diagnosis in slim individuals is frequently delayed. This article explains why lean people develop fatty liver, what symptoms to look for, how it is diagnosed on the NHS, and what can be done to manage it.

Can you get fatty liver disease if you are not overweight?

Yes, people with a normal or low BMI can develop fatty liver disease, known as lean NAFLD or lean MASLD, because fat accumulation in the liver is driven by metabolic dysfunction rather than body weight alone.

Yes, people who are slim or of a healthy weight can develop fatty liver disease. This is known as lean non-alcoholic fatty liver disease (lean NAFLD) or, under newer terminology adopted by international liver societies, lean metabolic dysfunction-associated steatotic liver disease (lean MASLD). The MASLD diagnosis requires evidence of fat accumulation in the liver (steatosis) alongside at least one cardiometabolic risk factor, with other causes of liver disease excluded.^[16][17] Fatty liver disease is not exclusively a condition of obesity, and research published in journals including the Journal of Hepatology has confirmed that a meaningful proportion of people diagnosed with NAFLD have a body mass index (BMI) within the normal range (below 25 kg/m² in European populations).^[15] This challenges the widespread assumption that only people who are visibly overweight are at risk.

It is worth noting that UK clinical practice recognises lower BMI thresholds for some ethnic groups. For example, South Asian adults may be at increased metabolic risk at a BMI below 23 kg/m², which is relevant when assessing fatty liver risk in people who appear slim by standard BMI criteria.^[5][6]

The condition occurs when excess fat accumulates within liver cells, impairing normal liver function. In lean individuals, this process can be just as damaging as in those with obesity. Some studies suggest lean NAFLD may be associated with worse outcomes in certain patient groups, though findings across cohorts are inconsistent, and this remains an active area of research. Clinicians and patients alike may overlook the possibility of liver disease in someone who appears slim, which can lead to delayed diagnosis.

Body weight and body composition are not the same thing. A person can have a normal BMI while still carrying excess fat around internal organs, a pattern sometimes called normal weight obesity or a high body fat percentage despite a low overall weight. This internal fat distribution is closely linked to metabolic risk, including the risk of fatty liver disease, regardless of outward appearance.

Why does fatty liver develop in lean people?

Lean fatty liver develops through genetic variants such as PNPLA3, insulin resistance, visceral fat, high refined carbohydrate intake, and certain medicines or medical conditions, all independent of overall body weight.

Lean fatty liver disease develops through a combination of genetic predisposition, metabolic dysfunction, and lifestyle factors that operate independently of body weight. One of the most studied genetic contributors is a variant in the PNPLA3 gene (encoding patatin-like phospholipase domain-containing protein 3), which impairs the liver's ability to process and export fat. Research published in journals including Hepatology has identified this variant as a significant risk factor for NAFLD across different populations. A variant in the TM6SF2 gene has also been associated with increased liver fat.^[25] Some studies suggest these variants may be more prevalent in certain ethnic groups, which could partly explain why fatty liver disease occurs at lower BMI thresholds in some populations, though the evidence on ethnicity-specific prevalence continues to evolve and should be interpreted with caution.

Insulin resistance is another central mechanism. Even in lean individuals, the liver can become resistant to insulin signalling, causing it to produce and retain excess fat. This metabolic dysfunction can occur without visible weight gain and may be driven by factors including a sedentary lifestyle, high intake of refined carbohydrates and fructose, and disrupted sleep patterns. Emerging research also points to gut microbiome composition as a possible contributing factor, though this remains an area of active investigation and findings should be regarded as preliminary. Visceral adiposity, meaning fat stored around the abdominal organs rather than under the skin, is a particularly important driver and can be present even when overall body weight is normal.

Certain medical conditions and medicines can also contribute. These include:

• Hypothyroidism, which slows fat metabolism

• Polycystic ovary syndrome (PCOS), associated with insulin resistance

• Coeliac disease, which may alter gut permeability and nutrient absorption

• Unsupervised crash dieting or malnutrition, which can paradoxically worsen liver fat by releasing large amounts of fatty acids into the bloodstream (note that supervised dietary interventions can improve NAFLD)

• Some medicines, including corticosteroids, amiodarone, tamoxifen, methotrexate, and certain antiretroviral drugs; readers should discuss any medicine-related concerns with their GP or pharmacist^[18]

Understanding these underlying mechanisms is important because it means that management of lean NAFLD must address metabolic health rather than simply focusing on weight reduction.

What are the signs and symptoms to watch for?

Lean fatty liver is usually silent early on; when symptoms occur they include persistent fatigue and upper right abdominal discomfort, and raised liver enzymes on blood tests may be the first clue.

Fatty liver disease in lean people is frequently silent in its early stages, meaning most individuals have no noticeable symptoms until the condition has progressed. It is often discovered incidentally, for example during an ultrasound scan performed for an unrelated reason or through abnormal results on routine blood tests. The absence of symptoms does not mean the liver is unaffected, and early-stage fat accumulation can still cause ongoing cellular damage.

When symptoms do occur, they tend to be non-specific and easy to attribute to other causes. These may include:

• Persistent fatigue that is disproportionate to activity levels

• A dull ache or discomfort in the upper right abdomen, where the liver sits

Some people with fatty liver disease also report difficulty concentrating, though this is a non-specific symptom with many possible causes and is not a reliable indicator of liver disease on its own.

Blood test findings that may prompt further investigation include raised liver enzymes, particularly alanine aminotransferase (ALT) or aspartate aminotransferase (AST). These are investigation findings rather than symptoms, and it is important to note that liver enzymes can be normal even when significant fat is present in the liver.

As the condition progresses to non-alcoholic steatohepatitis (NASH, now also termed metabolic dysfunction-associated steatohepatitis or MASH), inflammation and liver cell damage become more pronounced. In advanced cases, cirrhosis can develop.

Anyone who experiences persistent right-sided abdominal discomfort, unexplained fatigue, or who has received a result showing raised liver enzymes should speak to their GP.

The following symptoms may indicate more serious liver impairment and require prompt assessment. Contact NHS 111 or seek urgent medical attention if you develop:

• Jaundice (yellowing of the skin or whites of the eyes)

• Significant swelling of the abdomen

• New or worsening confusion or severe drowsiness

• Vomiting blood or passing black, tarry stools (which may indicate gastrointestinal bleeding)

• Easy or unexplained bruising

How is lean fatty liver disease diagnosed on the NHS?

Diagnosis follows NICE guideline NG49, starting with liver function tests and fibrosis scoring (FIB-4 or NFS), progressing to the ELF test, liver ultrasound, or FibroScan, with liver biopsy reserved for inconclusive cases.

Lean fatty liver disease is diagnosed through a combination of blood tests, imaging, and clinical assessment, following pathways broadly consistent with NICE guideline NG49 on non-alcoholic fatty liver disease. The first step is usually a GP consultation, where a clinical history is taken and blood tests are requested. These typically include liver function tests (LFTs), a fasting lipid profile, fasting glucose or HbA1c, and a full blood count.

In UK primary care, a common first step in assessing the degree of liver scarring (fibrosis) is calculating a fibrosis score using routine blood test results. The FIB-4 index and the NAFLD Fibrosis Score (NFS) are widely used non-invasive tools that help identify people at lower or higher risk of significant fibrosis, guiding decisions about further investigation.^[4][1] Age-adjusted cut-offs apply for FIB-4, and local Integrated Care Board (ICB) pathways may specify which scoring tool to use. Readers should follow the pathway recommended by their GP or local service.

The Enhanced Liver Fibrosis (ELF) test, a blood-based panel measuring markers of liver scarring, is recommended by NICE (NICE diagnostics guidance DG34) as a non-invasive way to assess the degree of fibrosis in people with suspected NAFLD, typically where first-line scoring suggests intermediate or higher risk.^[2][3] A liver ultrasound scan is commonly used to detect fat in the liver and can identify structural changes, though it is less sensitive for detecting early or mild steatosis. Where more detailed assessment is needed, a FibroScan (transient elastography) may be used to measure liver stiffness as a proxy for fibrosis, and is typically arranged following GP or hepatology review.

In lean individuals, it is particularly important that clinicians exclude other causes of liver disease before confirming a diagnosis of lean NAFLD. Standard exclusion tests in UK practice commonly include tests for viral hepatitis B and C, autoimmune hepatitis markers, iron studies (for haemochromatosis), coeliac serology, thyroid function, and copper studies (for Wilson's disease). Significant alcohol use must also be excluded, as this changes the diagnosis.

A liver biopsy remains the gold standard for definitive diagnosis and staging but is reserved for cases where non-invasive tests are inconclusive or where precise characterisation is needed before treatment decisions are made. Patients should ask their GP for a referral to a hepatologist if they have concerns about their liver health or if initial investigations suggest significant disease.

What lifestyle changes and treatments can help?

A Mediterranean-style diet, reduced fructose and alcohol intake, and at least 150 minutes of moderate exercise weekly are the main evidence-based interventions; no medicines are currently licensed in the UK specifically for NAFLD or MASLD.

Lifestyle modification remains the cornerstone of management for lean fatty liver disease, and evidence supports that even modest improvements in diet quality and physical activity can meaningfully reduce liver fat and inflammation. Unlike in people with obesity, the goal for lean individuals is not weight loss per se but rather improving metabolic health, reducing visceral fat, and addressing the specific dietary and lifestyle factors driving fat accumulation in the liver.

Dietary changes with the strongest evidence include:

• Reducing intake of fructose and added sugars, particularly from sugar-sweetened drinks and ultra-processed foods

• Following a Mediterranean-style diet, rich in vegetables, legumes, whole grains, oily fish, and olive oil; clinical studies and systematic reviews have shown this dietary pattern can reduce liver fat independently of weight change

• Reducing or avoiding alcohol, as even moderate alcohol intake can worsen liver inflammation in people with pre-existing steatosis; UK Chief Medical Officers advise that to keep health risks from alcohol low, it is safest not to drink more than 14 units per week on a regular basis, and people with fatty liver disease should discuss their individual alcohol intake with their GP or specialist^[11][12]

• Avoiding unsupervised crash dieting or severe calorie restriction, which can paradoxically worsen liver fat; supervised dietary interventions, by contrast, can improve NAFLD and should be discussed with a clinician

Regular physical activity is equally important. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have been shown to reduce liver fat and improve insulin sensitivity.^[22][23] UK Chief Medical Officers' physical activity guidelines recommend that adults aim for at least 150 minutes of moderate-intensity activity per week; the NHS provides further detail on how to achieve this.^[10][9]

Management of associated conditions such as hypothyroidism, dyslipidaemia, or insulin resistance may also be appropriate and should be discussed with a GP or specialist. It is worth noting that statins, where indicated for cardiovascular risk reduction, are generally considered safe in people with NAFLD and are not contraindicated by the liver condition itself; this should be discussed with a prescriber on an individual basis.

At present, there are no medicines specifically licensed in the UK for the treatment of NAFLD or MASLD; any pharmacological treatment is specialist-led and determined on an individual basis following review by a hepatologist or relevant specialist.^[14][13] Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online health consultations, with prescriber review and pharmacist support, and may be one option for people seeking guidance on metabolic health management alongside their NHS care. Patients with confirmed or suspected fatty liver disease should maintain regular follow-up with their GP or hepatology team to monitor for disease progression.

Scientific References

1. Non-alcoholic fatty liver disease (NAFLD) – Guideline NG49.
2. MRI-based technologies for assessing non-alcoholic fatty liver disease – ELF test recommendation (HTG655).
3. MRI-based technologies for assessing non-alcoholic fatty liver disease – Final scope (HTG655).
4. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317).
5. Overweight and obesity management – Identifying and assessing overweight, obesity and central adiposity (NG246).
6. Overweight and obesity management – Appendix A1: Summary of evidence from surveillance (NG246).
7. Non-alcoholic fatty liver disease (NAFLD).
8. Overweight and obesity.
9. Physical activity guidelines for adults aged 19 to 64.
10. Physical activity guidelines: UK Chief Medical Officers' report.
11. Alcohol consumption: advice on low risk drinking.
12. Drink less alcohol – Better Health.
13. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
14. Draft scope post-referral: MASLD/MASH pharmacological treatment (GID-TA11477).
15. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
16. Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications.
17. EASL position paper on preclinical models of steatotic liver disease.
18. Fatty liver and drugs: the two sides of the same coin.
19. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials.
20. Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis.
21. A systematic review and meta-analysis of randomized controlled trials: effects of Mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD.
22. The impact of long-term exercise on liver function, fatty liver progression, and related metabolic markers in NAFLD patients: a meta-analysis of randomized controlled trials.
23. Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
24. Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease.
25. Investigation of the impact of gynoid fat on steatotic and advanced liver diseases – genomic and clinical perspectives from a large-scale population cohort.

Frequently Asked Questions